Elbasvir-Grazoprevir Zepatier
Glecaprevir-Pibrentasvir Mavyret
Ledipasvir-Sofosbuvir Harvoni
Ribavirin Copegus, Rebetol, Ribasphere
Sofosbuvir Sovaldi
Sofosbuvir-Velpatasvir Epclusa
Sofosbuvir-Velpatasvir-Voxilaprevir Vosevi
Peginterferon alfa-2a Pegasys
Peginterferon alfa-2b PegIntronOfficial Title Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection.
Common TitleAIDS Clinical Trials Group A5071 Study
Common TitleAPRICOT Study
Official Title Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection
Official Title Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection
Official Title Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection
Official Title Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis
Official Title Sofosbuvir and Velpatasvir for the Treatment of HCV in Patients Coinfected with HIV-1: an Open-Label, Phase 3 Study
Official Title The ATOMIC Study: A Multicenter, Open-label, Randomized, Duration Finding Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Following Oral Administration of PSI-7977 in Combination With Pegylated Interferon and Ribavirin in Treatment-Naive Patients With Chronic HCV Infection Genotype 1,4, 5, or 6
Official Title Efficacy of Sofosbuvir plus Ribavirin with or without Peginterferon-alfa in Patients with Hepatitis C Virus Genotype 3 Infection and Treatment-Experienced Patients with Cirrhosis and Hepatitis C virus Genotype 2 Infection.
Official Title Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial
Official Title Efficacy and Safety of Grazoprevir (MK-5172) and Elbasvir (MK-8742) in Patients with Hepatitis C Virus and HIV Co-Infection (C-EDGE CO-INFECTION): a Non-Randomised, Open-Label Trial
Official Title Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients With Chronic Hepatitis C Infection
Official Title Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial
Official Title Elbasvir/grazoprevir and sofosbuvir for hepatitis C virus genotype 3 infection with compensated cirrhosis: A randomized trial.
Official Title Grazoprevir, Elbasvir, and Ribavirin for Chronic Hepatitis C Virus Genotype 1 Infection After Failure of Pegylated Interferon and Ribavirin With an Earlier-Generation Protease Inhibitor: Final 24-Week Results From C-SALVAGE
Common TitleC-SCAPE
Official Title Efficacy and safety of 12 weeks of elbasvir ± grazoprevir ± ribavirin in participants with hepatitis C virus genotype 2, 4, 5 or 6 infection: The C-SCAPE study.
Official Title Grazoprevir plus Elbasvir in Treatment-Naive and Treatment-Experienced Patients with Hepatitis C Virus Genotype 1 Infection and Stage 4-5 Chronic Kidney Disease (the C-SURFER study): a Combination Phase 3 Study.
Official Title Short-Duration Treatment with Elbasvir/Grazoprevir and Sofosbuvir for Hepatitis C: a Randomized Trial
Official Title Efficacy and Safety of 12 Weeks versus 18 Weeks of Treatment with Grazoprevir (MK-5172) and Elbasvir (MK-8742) with or without Ribavirin for Hepatitis C Virus Genotype 1 Infection in Previously Untreated Patients with Cirrhosis and Patients with Previous Null Response with or without Cirrhosis (C-WORTHY): a Randomised, Open-Label Phase 2 Trial.
Official Title Efficacy and Safety of 8 weeks versus 12 weeks of Treatment with Grazoprevir (MK-5172) and Elbasvir (MK-8742) with or without Ribavirin in Patients with Hepatitis C virus Genotype 1 Mono-Infection and HIV/hepatitis C virus Co-Infection (C-WORTHY): a Randomised, Open-Label Phase 2 Trial.
Official Title Sofosbuvir plus Ribavirin for the Treatment of Chronic Genotype 4 Hepatitis C virus Infection in Patients of Egyptian Ancestry.
Official Title Ledipasvir/sofosbuvir with or without ribavirin for 8 or 12 weeks for the treatment of HCV genotype 4 infection: results from a randomised phase III study in Egypt.
Official Title Efficacy of Nucleotide Polymerase Inhibitor Sofosbuvir plus the NS5A Inhibitor Ledipasvir or the NS5B Non-Nucleoside inhibitor GS-9669 Against HCV Genotype 1 Infection.
Official Title Efficacy of Nucleotide Polymerase Inhibitor sofosbuvir plus the NS5A Inhibitor Ledipasvir or the NS5B Non-Nucleoside inhibitor GS-9669 Against HCV Genotype 1 Infection.
Official Title Nucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis C
Official Title Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection.
Official Title Efficacy of Glecaprevir/Pibrentasvir for 12 Weeks in Patients with HCV Genotype 2, 4, 5, or 6 Infection Without Cirrhosis.
Official Title Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection.
Official Title Efficacy of Glecaprevir/Pibrentasvir for 12 Weeks in Patients with HCV Genotype 2, 4, 5, or 6 Infection Without Cirrhosis.
Official Title Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus genotype 5 or 6 infection (ENDURANCE-5,6): an open-label, multicentre, phase 3b trial.
Official Title Effectiveness, Treatment Completion and Safety of Sofosbuvir-Ledipasvir and Paritaprevir-Ritonavir-Ombitasvir plus Dasabuvir in Patients with Chronic Kidney Disease: an ERCHIVES Study.
Official Title Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial.
Official Title Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Co-infected With Hepatitis C Virus and Human Immunodeficiency Virus-1: The EXPEDITION-2 Study
Official Title Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment.
Official Title Efficacy and Safety of glecaprevir/pibrentasvir in Renally Impaired Patients With Chronic HCV Infection
Official Title A Single Arm, Open-label Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment Naïve Adults With Chronic Hepatitis C Virus (HCV) Genotype 1-6 Infection and Compensated Cirrhosis
Official Title Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
Official Title Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options
Official Title Safety and Pharmacokinetics of Glecaprevir/Pibrentasvir in Adults With Chronic Genotype 1-6 Hepatitis C Virus Infections and Compensated Liver Disease
Official Title Safety and Efficacy of Sofosbuvir-Containing Regimens in Hepatitis C-Infected Patients with Impaired Renal Function
Official Title A Phase 3b, Multi-Center, Randomized, Open-Label, Pragmatic Study of Glecaprevir/Pibrentasvir (G/P) +/- Ribavirin for GT1 Subjects With Chronic Hepatitis C Previously Treated With an NS5A Inhibitor + Sofosbuvir Therapy
Common TitleIDEAL Study
Official Title Safety and Efficacy of Elbasvir/Grazoprevir in Patients With Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis
Official Title Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection
Official Title Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection.
Official Title Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
Official Title Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1
Official Title Sofosbuvir and Ledipasvir Fixed-Dose Combination with and without Ribavirin in Treatment-Naive and Previously Treated Patients with Genotype 1 Hepatitis C Virus Infection (LONESTAR): an Open-Label, Randomised, Phase 2 Trial
Official Title Sofosbuvir with Peginterferon-Ribavirin for 12 Weeks in Previously Treated Patients with Hepatitis C Genotype 2 or 3 and Cirrhosis
Official Title Glecaprevir and Pibrentasvir for 12 Weeks for Hepatitis C Virus Genotype 1 Infection and Prior Direct-Acting Antiviral Treatment.
Official Title Glecaprevir/Pibrentasvir in Patients with HCV Genotype 1 or 4 and Prior Direct-acting Antiviral Treatment Failure.
Official Title An Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Glecaprevir-Pibrentasvir in Combination With Sofosbuvir and Ribavirin in Chronic Hepatitis C (HCV) Infected Subjects Who Have Experienced Virologic Failure in AbbVie HCV Clinical Studies (MAGELLAN-3).
Official Title A Single-arm Study to Evaluate the Feasibility and Efficacy of a Minimal Monitoring Strategy to Deliver Pan-genotypic Ribavirin-free HCV Therapy to HCV Infected Populations Who Are HCV Treatment Naïve With Evidence of Active HCV Infection: The MINMON Study
Official Title Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection.
Official Title Efficacy of Ledipasvir and Sofosbuvir, with or without Ribavirin, for 12 Weeks inPatients with HCV Genotype 3 or 6 Infection
Official Title Virologic Response following Combined Ledipasvir and Sofosbuvir Administration in Patients with HCV Genotype 1 and HIV Co-Infection
Official Title Re-Treatment of Chronic Hepatitis C Virus Genotype 1 Infection after Relapse: an Open-Label Pilot Study.
Official Title Sofosbuvir and Ribavirin for Hepatitis C Genotype 1 in Patients with Unfavorable Treatment Characteristics: a Randomized Clinical Trial
Official Title Virological Response after 6 Week Triple-Drug Regimens for Hepatitis C: a Proof-of-Concept Phase 2A Cohort Study
Official Title Ledipasvir and Sofosbuvir for Hepatitis C Genotype 4: a Proof-of-Concept, Single-Centre, Open-Label Phase 2a Cohort Study
Common TitlePeginterferon alfa-2a versus Interferon alfa-2a
Common TitlePeginterferon alfa-2a with or without Ribavirin
Official Title Sofosbuvir and Ribavirin for Hepatitis C in Patients with HIV Coinfection
Official Title Sofosbuvir plus Ribavirin for Treatment of Hepatitis C Virus in Patients Co-Infected with HIV (PHOTON-2): A Multicentre, Open-Label, Non-randomised, Phase 3 Study
Official Title Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection
Official Title Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials
Official Title Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials.
Official Title Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection
Official Title Efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 4 infection: A pooled analysis.
Official Title Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options
Official Title Sofosbuvir in Combination with Peginterferon alfa-2a and Ribavirin for Non-cirrhotic, Treatment-naive Patients with Genotypes 1, 2, and 3 Hepatitis C Infection: A Randomised, Double-Blind, Phase 2 Trial.
Official Title Safety Study of Regimens of Sofosbuvir, GS-0938, and Ribavirin in Patients With Chronic Hepatitis C Infection (QUANTUM)
Official Title A pilot study of safety and efficacy of HCV retreatment with sofosbuvir/velpatasvir/voxilaprevir in patients with or without HIV (RESOLVE STUDY)
Common TitleRetreatment of Sofosbuvir Failure
Official Title Ledipasvir-Sofosbuvir plus Ribavirin for Patients with Genotype 1 Hepatitis C Virus Previously Treated in Clinical Trials of Sofosbuvir Regimens
Official Title Ledipasvir-sofosbuvir with or without Ribavirin to Treat Patients with HCV Genotype 1 Infection and Crrhosis Non-Responsive to Previous Protease-Inhibitor Therapy: a Randomised, Double-Blind, Phase 2 Trial (SIRIUS)
Common TitleSOF-VEL-VOX in G/P Failure
Official Title Sofosbuvir/Velpatasvir/Voxilaprevir for Previous Treatment Failures With Glecaprevir/Pibrentasvir in Chronic Hepatitis C Infection
Official Title Sofosbuvir for Chronic Hepatitis C Virus Infection Genotype 1-4 in Patients Coinfected with HIV.
Official Title Sofosbuvir and Ribavirin for Treatment of Compensated Recurrent Hepatitis C Virus Infection after Liver Transplantation
Official Title Sofosbuvir and Ribavirin prevent Recurrence of HCV Infection After Liver Transplantation: An Open-Label Study
Common TitleSofosbuvir-Velpatasvir in Patients with Compensated Cirrhosis and HCV Genotype 3 (Spain) Industry
Official Title Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and Cirrhosis
Official Title Efficacy and safety of sofosbuvir–velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial
Official Title Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis
Official Title Ledipasvir and Sofosbuvir plus Ribavirin for Treatment of HCV Infection in Patients with Advanced Liver Disease.
Official Title Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial
Official Title Glecaprevir and Pibrentasvir Yield High Response Rates in Patients with HCV Genotype 1-6 without Cirrhosis.
Official Title Glecaprevir/Pibrentasvir for HCV Genotype 3 Patients with Cirrhosis and/or Prior Treatment Experience: A Partially Randomized Phase III Clinical Trial.
Official Title Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients with HCV Genotype 2, 4, 5, or 6 Infection Without Cirrhosis.
Official Title A Phase III, Multi-center, Open-label Trial to Investigate the Impact of a Treat, Counsel and Cure Strategy in Men Who Have Sex With Men With Hepatitis C Infection in the Swiss HIV Cohort Study
Official Title Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3
No trials match those search criteria.